Entresto costs between $600 and $900 per month at full cash price, making it one of the most expensive heart failure medications on the market. Several factors drive that price: it’s a first-in-class drug with no generic equivalent, it required massive clinical trials to prove its superiority over older treatments, and until recently, Novartis faced virtually no competition in its drug class. The good news is that the price landscape is shifting, with a Medicare-negotiated price of $295 per month taking effect in January 2026.
What Makes Entresto Different From Older Drugs
Entresto isn’t just another blood pressure pill repurposed for heart failure. It combines two active ingredients that work through separate pathways simultaneously. One component blocks the hormone system that constricts blood vessels and raises blood pressure. The other prevents the breakdown of natural proteins your body produces to relax blood vessels, reduce fluid retention, and protect heart muscle. No previous drug could do both at once.
This dual action translates into measurable clinical advantages. In the landmark PARADIGM-HF trial, Entresto reduced cardiovascular death by 20% compared to enalapril, a widely used older drug. It also lowered the risk of hospitalization for heart failure, reduced symptoms, and improved physical function. At the cellular level, Entresto slows the scarring process in heart tissue that makes heart failure progressively worse. These are not marginal improvements over generic alternatives that cost less than $10 a month, and Novartis priced the drug to reflect that gap.
No Generic Competition Until Recently
For most of its commercial life, Entresto had no competitors in the ARNI drug class. Older heart failure medications like lisinopril, enalapril, and losartan have been available as generics for years, some costing under $10 per month. But none of them work through the same dual mechanism, so they aren’t true substitutes.
Novartis held key patents on Entresto, including one that didn’t expire until January 2025 after a patent term extension. When generic manufacturers like MSN and Torrent Pharma filed applications with the FDA to sell cheaper versions, Novartis took them to court. These patent disputes wound through the federal appeals system, delaying generic entry and preserving Novartis’s pricing power for years. Without a generic on pharmacy shelves, there was no market pressure to lower the price.
The Scale of Clinical Investment
Bringing a new drug class to market is extraordinarily expensive, and pharmaceutical companies build those costs into the price. The PARADIGM-HF trial alone enrolled over 8,000 patients across multiple countries and ran long enough to measure differences in death rates, not just symptoms. Novartis then conducted additional trials in different patient populations, including studies on starting Entresto in the hospital after an acute heart failure episode. Each of these trials required thousands of patients, years of follow-up, and regulatory submissions in dozens of countries. While Novartis has not disclosed a specific R&D figure for Entresto, the scope of this clinical program was among the largest in cardiovascular medicine.
Medicare Negotiation Cuts the Price in Half
Entresto was one of the first ten drugs selected for price negotiation under the Inflation Reduction Act’s Medicare Drug Price Negotiation Program. The results were significant. Against a 2023 list price of $628 for a 30-day supply, the negotiated price came in at $295, a 53% discount. This new price takes effect January 1, 2026, and applies to Medicare Part D enrollees.
The scale of Medicare spending on Entresto helps explain why it was targeted. In 2023, total Part D costs for the drug exceeded $3.4 billion, with roughly 664,000 Medicare enrollees filling prescriptions. That combination of high per-patient cost and large patient volume made it a priority for negotiation. If you’re on Medicare Part D, your out-of-pocket costs for Entresto should drop substantially starting in 2026.
What Independent Analysts Say About Fair Pricing
The Institute for Clinical and Economic Review, a nonprofit that evaluates whether drug prices match their clinical value, analyzed Entresto shortly after its launch. ICER concluded that the drug’s wholesale acquisition cost of $4,560 per year would need to drop to about $4,168, roughly a 9% discount, to avoid placing an excessive cost burden on the health care system. That relatively modest recommended discount reflects the fact that Entresto genuinely reduces hospitalizations and deaths. In other words, even independent analysts acknowledged the drug delivers substantial value. The problem for patients has always been that value-based pricing at the system level doesn’t help much when you’re staring at a $700 monthly pharmacy bill.
Ways to Lower Your Cost Now
If you’re uninsured or on government insurance, the Novartis Patient Assistance Foundation provides Entresto at no cost to eligible patients. It’s a nonprofit program, separate from Novartis’s commercial operations. To qualify, you need to live in the United States, be treated by a licensed provider on an outpatient basis, and meet income guidelines. The application requires proof of income and, in some cases, evidence that you were denied Medicare’s Extra Help program. You or a legal guardian must submit the application directly. Expect a decision within about four weeks.
For patients with commercial insurance, Novartis offers copay assistance cards that can reduce monthly out-of-pocket costs significantly. Your pharmacist or cardiologist’s office can typically point you to the right program. It’s also worth asking your pharmacist to compare prices across pharmacies, since cash prices for Entresto can vary by hundreds of dollars depending on where you fill the prescription.
The Bigger Picture on Heart Failure Drug Costs
Heart failure is one of the most common reasons for hospital admission in the United States, and each hospitalization can cost tens of thousands of dollars. Entresto’s ability to reduce those admissions is part of why insurers generally cover it despite the high sticker price. For the health care system as a whole, paying $600 a month for a drug that prevents a $30,000 hospital stay can be a net savings. That math doesn’t make the pharmacy counter any less painful, but it explains why payers have been willing to keep the drug on formularies rather than forcing patients onto cheaper, less effective alternatives.
With the Medicare negotiated price arriving in 2026 and generic applications working through the FDA, the cost picture for Entresto is likely to look very different within the next few years. Until then, patient assistance programs and copay cards remain the most practical tools for managing the expense.